Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

This is an Experimental Substance with little data. This is most likely because the substance is is not very old. Information is limite and incomplete.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

25B-NBOH Also known as:

  • 2-({[2-(4-Brom-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol[German][ACD/IUPAC Name]
  • 2-({[2-(4-Bromo-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol[ACD/IUPAC Name]
  • 2-({[2-(4-Bromo-2,5-diméthoxyphényl)éthyl]amino}méthyl)phénol[French][ACD/IUPAC Name]
  • Phenol, 2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-[ACD/Index Name]

A phenethylamine psychedelic and stimulant derivative of 2C-B, this compound is related to and has similar effects to 25b-NBOMe. It is significantly more potent than 2C-B but less potent than 25B-NBOMe. Overdoses of NBOH compounds may cause dangerous vasoconstriction. May induce uncomfortable body load.

Summary

It is a closely related analog of 25B-NBOMe and is reported to share most of its properties with the exception of a moderately reduced potency and a shorter duration. The name 25B-NBOH, which is short-hand for 2C-B-NBOH, is a derivative of the phenethylamine psychedelic 2C-B. It was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen.

It is worth noting that compounds of the NBOH family are not orally active and should be administered sublingually by placing and holding it into one’s mouth and allowing it to absorb over a period of 15-25 minutes. Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25B-NBOH in humans. It has no history of human use before being sold online as a designer drug in 2011.

It is closely related to members of the 25x-NBOMe series, which have been associated with many hospitalizations and deaths. Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.

Chemistry

25B-NBOH

25B-NBOH

25B-NBOH is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as an bromine atom attached to carbon R4.

It differs from 2C-B structurally through a substitution on the amine (NH2) with a 2-hydroxybenzyl (BOH) group.

25B-NBOH shares this 2-hydroxybenzyl substitution with other chemicals of the NBOH family.

This NBOH addition is comprised of a hydroxy ether OH- bound to a benzene ring at R2.

Common Name25B-NBOH
Systematic name25B-NBOH
FormulaC_{17}H_{20}BrNO_{3}
SMILESCOc1cc(c(cc1Br)OC)CCNCc2ccccc2O
Std. InChiInChI=1S/C17H20BrNO3/c1-21-16-10-14(18)17(22-2)9-12(16)7-8-19-11-13-5-3-4-6-15(13)20/h3-6,9-10,19-20H,7-8,11H2,1-2H3
Std. InChiKeyRSUNJYKZRKIBNB-UHFFFAOYSA-N
Avg. Mass366.2496 Da
Molecular Weight366.2496
Monoisotopic Mass365.062653 Da
Nominal Mass365
ChemSpider ID58191433

Subscribe for the latest updates

Dose Chart

Sublingually
Light200-400ug
Common400-800ug
Strong800ug-1mg.

Duration Chart

25B-NBOH Duration Data
Onset20-40 minutes
Duration4-10 hours
After-effects1-12 hours

Auditory Effects

Psychological Effects

The cognitive effects of 25B-NBOH are described by many as notably light in comparison to the classical psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, strong to overwhelming cognitive alterations become present, which can lead to states of confusion, amnesia, and general sensory overload. The most prominent of these cognitive effects generally include:

Pharmacological Effects

25B-NBOH has efficacy at the 5-HT2A receptor where it acts as a potent agonist. This compound is pharmacologically unique when compared to other psychedelics due to the unusually high selectivity it displays for various serotonin receptors. It is notable as one of the most selective agonist ligands for the 5-HT2A receptor with a pEC50 value of 9.87 nMIt has a pKi of 0.061 nM at the human 5HT2A receptor, similar to the better-known compound 25B-NBOMe. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Physical Effects

Sensory Effects

  • Dosage independent intensity - While the reasons for this are not understood, many reports suggest that this substance can produce unexpectedly strong or weak effects even when taken at the seemingly same dose in an unpredictable manner. This may contribute to the relative risk it is poses compared to most other psychedelics.
  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Subjective Effects

Visual Effects

Enhancements

Suppressions

Distortions

Geometry

The visual geometry produced by this substance is similar to LSD and can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colorful in scheme, glossy in color, sharp around the edges and equally angular as well as rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within 2C-I and most of the 2C-x family in general as well as completely on par with LSD, Psilocin and DMT at appropriately high dosages.

25B-NBOH’s geometry leads reliably leads to Level 8A visual geometry with Level 8B remaining so far unconfirmed. It seems to consistently be able to build up in visual intensity when the user stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.

Hallucinatory states

25B-NBOH is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very different and inconsistent in comparison to other more commonly used psychedelics such as psilocin, 2C-E and DMT.

These effects include:

Legal Status

  • Brazil: As of December 10, 2018, 25B-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.
  • Germany: 25B-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Sweden: The Riksdag added 25B-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12
  • United Kingdom: 25B-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.
  • United States: 25B-NBOH is not a controlled substance in the United States but possession or distribution for human use could potentially be prosecuted under the Federal Analogue Act due to its structural and pharmacological similarities to 25B-NBOMe.
  • Sources

    References

    1. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    2. Martin Hansen (2011). "Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain." University of Copenhagen. Retrieved 27 June 2015.
    3. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
    4. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
    5. Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
    6. Silva, M. E., Heim, R., Strasser, A., Elz, S., & Dove, S. (2011). Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. Journal of Computer-aided Molecular Design, 25(1), 51-66. https://doi.org/10.1007/s10822-010-9400-2
    7. Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMC 3963123. PMID 24397362. https://doi.org/10.1021/cn400216u
    8. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    9. List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial
    10. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
    11. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    12. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
    13. https://lakemedelsverket.se/upload/lvfs/HSLF_FS_2015_12.pdf
    14. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.